GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (LTS:0HOJ) » Definitions » Shiller PE Ratio

Blueprint Medicines (LTS:0HOJ) Shiller PE Ratio : (As of Jun. 12, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Blueprint Medicines Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Blueprint Medicines Shiller PE Ratio Historical Data

The historical data trend for Blueprint Medicines's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Shiller PE Ratio Chart

Blueprint Medicines Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Blueprint Medicines Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Blueprint Medicines's Shiller PE Ratio

For the Biotechnology subindustry, Blueprint Medicines's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Blueprint Medicines's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Blueprint Medicines's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Blueprint Medicines's Shiller PE Ratio falls into.



Blueprint Medicines Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Blueprint Medicines's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Blueprint Medicines's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.4/131.7762*131.7762
=1.400

Current CPI (Mar. 2024) = 131.7762.

Blueprint Medicines Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.733 100.560 -0.961
201409 -0.903 100.428 -1.185
201412 -1.251 99.070 -1.664
201503 -0.556 99.621 -0.735
201506 -0.810 100.684 -1.060
201509 -0.470 100.392 -0.617
201512 -0.580 99.792 -0.766
201603 -0.570 100.470 -0.748
201606 -0.700 101.688 -0.907
201609 -0.620 101.861 -0.802
201612 -0.750 101.863 -0.970
201703 -0.840 102.862 -1.076
201706 -0.860 103.349 -1.097
201709 -0.960 104.136 -1.215
201712 -1.230 104.011 -1.558
201803 -1.290 105.290 -1.615
201806 -0.620 106.317 -0.768
201809 -1.660 106.507 -2.054
201812 -1.830 105.998 -2.275
201903 -1.980 107.251 -2.433
201906 -2.040 108.070 -2.488
201909 -1.930 108.329 -2.348
201912 -1.350 108.420 -1.641
202003 -2.110 108.902 -2.553
202006 -2.280 108.767 -2.762
202009 11.160 109.815 13.392
202012 -1.530 109.897 -1.835
202103 -1.720 111.754 -2.028
202106 -1.860 114.631 -2.138
202109 -2.000 115.734 -2.277
202112 -5.400 117.630 -6.049
202203 -1.790 121.301 -1.945
202206 -2.680 125.017 -2.825
202209 -2.230 125.227 -2.347
202212 -2.650 125.222 -2.789
202303 -2.150 127.348 -2.225
202306 -2.190 128.729 -2.242
202309 -2.200 129.860 -2.232
202312 -1.820 129.419 -1.853
202403 1.400 131.776 1.400

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Blueprint Medicines  (LTS:0HOJ) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Blueprint Medicines Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Blueprint Medicines (LTS:0HOJ) Business Description

Traded in Other Exchanges
Address
45 Sidney Street, Cambridge, MA, USA, 02139
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

Blueprint Medicines (LTS:0HOJ) Headlines

No Headlines